Azacitidine Drug Asset Due Diligence Report 2026

This Azacitidine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

959

Registered trials

986

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Azacitidine can convert its Small molecule drug profile and DNMT1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Azacitidine (query alias: Azacitidine)
Modality / target	Small molecule drug; DNMT1; DNMT1 inhibitors, DNA methylation inhibitors, Epigenetic drug
Highest global status	Approved
Originator	Celgene Corp.
Active developers	Celgene Corp., Accord Healthcare SL, AbbVie, Inc.

The MCP disease footprint includes Juvenile Myelomonocytic Leukemia, Myeloproliferative Disorders, Philadelphia chromosome positive chronic myelogenous leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07686965	Phase 3	Not yet recruiting	191	Disease-Free Survival
NCT07691450	Phase 1	Not yet recruiting	40	Occurrence of dose-limiting toxicities (DLT) (Arm A)
NCT07679334	Phase 1	Not yet recruiting	20	To determine the maximum tolerated dose (MTD) of the treatment regimen.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (Aged 18-59) With Acute Myeloid Leukemia

Phase 2; n=36; evaluation: not stated. Reported fields: Response Rate, Measured by the European Leukemia Net Definition: (CRMRD-+CR+CRi+MLFS) = 25 Participants ; -; -

A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent

Phase 2; n=7; evaluation: not stated. Reported fields: Neutropenia CTCAE Grade ≥3 = 2 Participants ; -; -

Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies.

Phase 1; n=59; evaluation: Positive. Reported fields: ORR = 100.0 % ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Azacitidine addresses Juvenile Myelomonocytic Leukemia, Myeloproliferative Disorders, Philadelphia chromosome positive chronic myelogenous leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-03-19	Knight to commercialize Bristol-Myers Squibb's Vidaza and Abraxane for myelodysplastic syndrome and metastaticpancreatic adenocarcinoma in Brazil	Approved	Financial terms not disclosed
2018-06-04	MD Anderson will initiate a phase I clinical trial investigating the combination of Agios' ivosidenib or enasidenib with azacitidine for the treatment of acute myeloid leukemia (AML).	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Fixed dose combinations of cedazuridine and azacitidine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO